Compound Evidence File
#EC-2026-0968
LGD-4033 (Ligandrol) Raw
Filed under Raw Materials. The bureau holds 127 laboratory returns for this compound from 45 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
45 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 10.0 | 10.0 | 10.0 | 15 Nov 2025 | 2 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 21 Feb 2026 | 24 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 10.0 | 9.9 | 10.0 | 18 Dec 2025 | 24 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 10.0 | 10.0 | 10.0 | 18 Dec 2025 | 17 Aug 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 9.9 | 10.0 | 11 May 2026 | 5 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 3 Mar 2026 | 28 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 9.9 | 10.0 | 15 Jan 2026 | 9 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 9.9 | 10.0 | 19 Jan 2026 | 28 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 19 Apr 2026 | 13 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 9.9 | 10.0 | 15 Mar 2026 | 25 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 9.9 | 10.0 | 10 Jun 2026 | 24 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 10.0 | 10.0 | 10.0 | 27 Mar 2026 | 7 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 10.0 | 10.0 | 10.0 | 11 Dec 2025 | 6 May 2026 |
| NUPEPS PeptidesCASE #VI-2026-0896 | X | 1 | 10.0 | 10.0 | 10.0 | 13 Jun 2025 | 13 Jun 2025 |
| HomopeptideCASE #VI-2026-0760 | A | 5 | 9.9 | 9.9 | 10.0 | 25 May 2026 | 25 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 9.9 | 9.9 | 10.0 | 20 Feb 2026 | 16 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 11 Feb 2026 | 23 May 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Jan 2026 | 7 Aug 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 19 Apr 2026 | 9 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 9.9 | 26 Jun 2026 | 3 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 10.0 | 2 Apr 2026 | 27 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 9.9 | 9 Apr 2026 | 13 Aug 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 9.9 | 9.9 | 9.9 | 24 Jul 2026 | 26 Jul 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 9.2 | 8.7 | 9.7 | 25 May 2026 | 25 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 9.1 | 8.3 | 9.8 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.8 | 6.8 | 10.0 | 24 May 2026 | 24 May 2026 |
| Huaian Hanyou PeptideCASE #VI-2026-0297 | X | 1 | 8.6 | 8.6 | 8.6 | 20 Jun 2025 | 20 Jun 2025 |
| Haikou Mingheng TechnologyCASE #VI-2026-0250 | X | 1 | 8.3 | 8.3 | 8.3 | 3 Jul 2025 | 3 Jul 2025 |
| Tianjin Ruiwang New Material Technology CoCASE #VI-2026-0192 | X | 3 | 8.2 | 6.7 | 9.8 | 6 May 2025 | 25 May 2026 |
| Astro PeptidesCASE #VI-2026-0424 | X | 1 | 8.2 | 8.2 | 8.2 | 27 Feb 2025 | 27 Feb 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 4 | 8.0 | 6.5 | 9.7 | 23 May 2026 | 23 May 2026 |
| Diju Peptides Wellness and CoCASE #VI-2026-0724 | X | 1 | 8.0 | 8.0 | 8.0 | 21 May 2025 | 21 May 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 7.9 | 6.5 | 9.6 | 23 May 2026 | 23 May 2026 |
| Bulk Peptide SupplyCASE #VI-2026-0446 | X | 2 | 7.7 | 7.2 | 8.2 | 2 Jul 2025 | 24 May 2026 |
| The Naughty NeedleCASE #VI-2026-0432 | X | 1 | 7.1 | 7.1 | 7.1 | 13 Jun 2025 | 13 Jun 2025 |
| NexaphCASE #VI-2026-0944 | X | 7 | 7.0 | 6.3 | 8.2 | 17 Dec 2024 | 19 Jan 2026 |
| Planet PeptideCASE #VI-2026-0092 | X | 4 | 7.0 | 4.8 | 7.9 | 27 Feb 2025 | 21 May 2026 |
| Bio PepzCASE #VI-2026-0436 | X | 1 | 7.0 | 7.0 | 7.0 | 17 Dec 2024 | 17 Dec 2024 |
| Oasis PeptidesCASE #VI-2026-0404 | X | 1 | 6.7 | 6.7 | 6.7 | 6 May 2025 | 6 May 2025 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 6.6 | 6.6 | 6.6 | 3 Jun 2025 | 3 Jun 2025 |
| DeuschemCASE #VI-2026-0004 | X | 1 | 6.5 | 6.5 | 6.5 | 3 Jun 2025 | 3 Jun 2025 |
| Qingdao Hongshengda TradingCASE #VI-2026-0334 | X | 1 | 6.3 | 6.3 | 6.3 | 27 Feb 2025 | 27 Feb 2025 |
| Shenzhen Loga Tech LG LOGACASE #VI-2026-0920 | X | 2 | 6.1 | 5.6 | 6.6 | 25 Apr 2025 | 23 May 2026 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 5.4 | 5.4 | 5.4 | 2 Jul 2025 | 2 Jul 2025 |
Open any subject to view the batch-level evidence for LGD-4033 (Ligandrol) Raw alone.